Linde’s shares fell 1.0% after earnings, a roughly flat reaction. Sales and EPS reached quarterly records, but underlying growth was concentrated by end market and geography, while operating margin was down year over year and flat excluding cost pass-through.
- Sales were $9.4 billion, up 9%; underlying sales growth was 5% after currency, cost pass-through, acquisitions and engineering contributions.
- Volume rose 2%, roughly split between project backlog and organic growth; prices increased 3%, partly reflecting inflation recovery.
- Operating profit grew 8% to $2.8 billion, and EPS was $4.59. Operating margin was 29.4%, down 30 basis points year over year and flat excluding cost pass-through.
- Growth varied across markets: electronics rose 15%, chemicals and energy 12%, manufacturing 7%, food and beverage 3%, and healthcare 2%; healthcare growth was mid-single digit excluding Lincare.
- Linde recorded a $425 million restructuring charge, primarily for severance and portfolio and asset actions. Management is restructuring Lincare and evaluating strategic alternatives.
Community Discussion